BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Valanparambil, Rajesh M., Lai, Lilin, Johns, Margaret A., Davis-Gardner, Meredith, Linderman, Susanne L., McPherson, Tarrant Oliver, Chang, Andres, Akhtar, Akil, Gamarra, Estefany L. Bocangel, Matia, Hayley, McCook-Veal, Ashley A., Switchenko, Jeffrey, Nasti, Tahseen H., Green, Felicia, Saini, Manpreet, Wieland, Andreas, Pinsky, Benjamin A., Solis, Daniel, Dhodapkar, Madhav V., Carlisle, Jennifer, Ramalingam, Suresh, Ahmed, Rafi, Suthar, Mehul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663480/
https://www.ncbi.nlm.nih.gov/pubmed/37990024
http://dx.doi.org/10.1038/s41541-023-00779-8
_version_ 1785148645309415424
author Valanparambil, Rajesh M.
Lai, Lilin
Johns, Margaret A.
Davis-Gardner, Meredith
Linderman, Susanne L.
McPherson, Tarrant Oliver
Chang, Andres
Akhtar, Akil
Gamarra, Estefany L. Bocangel
Matia, Hayley
McCook-Veal, Ashley A.
Switchenko, Jeffrey
Nasti, Tahseen H.
Green, Felicia
Saini, Manpreet
Wieland, Andreas
Pinsky, Benjamin A.
Solis, Daniel
Dhodapkar, Madhav V.
Carlisle, Jennifer
Ramalingam, Suresh
Ahmed, Rafi
Suthar, Mehul S.
author_facet Valanparambil, Rajesh M.
Lai, Lilin
Johns, Margaret A.
Davis-Gardner, Meredith
Linderman, Susanne L.
McPherson, Tarrant Oliver
Chang, Andres
Akhtar, Akil
Gamarra, Estefany L. Bocangel
Matia, Hayley
McCook-Veal, Ashley A.
Switchenko, Jeffrey
Nasti, Tahseen H.
Green, Felicia
Saini, Manpreet
Wieland, Andreas
Pinsky, Benjamin A.
Solis, Daniel
Dhodapkar, Madhav V.
Carlisle, Jennifer
Ramalingam, Suresh
Ahmed, Rafi
Suthar, Mehul S.
author_sort Valanparambil, Rajesh M.
collection PubMed
description This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
format Online
Article
Text
id pubmed-10663480
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106634802023-11-21 BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer Valanparambil, Rajesh M. Lai, Lilin Johns, Margaret A. Davis-Gardner, Meredith Linderman, Susanne L. McPherson, Tarrant Oliver Chang, Andres Akhtar, Akil Gamarra, Estefany L. Bocangel Matia, Hayley McCook-Veal, Ashley A. Switchenko, Jeffrey Nasti, Tahseen H. Green, Felicia Saini, Manpreet Wieland, Andreas Pinsky, Benjamin A. Solis, Daniel Dhodapkar, Madhav V. Carlisle, Jennifer Ramalingam, Suresh Ahmed, Rafi Suthar, Mehul S. NPJ Vaccines Brief Communication This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern. Nature Publishing Group UK 2023-11-21 /pmc/articles/PMC10663480/ /pubmed/37990024 http://dx.doi.org/10.1038/s41541-023-00779-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Valanparambil, Rajesh M.
Lai, Lilin
Johns, Margaret A.
Davis-Gardner, Meredith
Linderman, Susanne L.
McPherson, Tarrant Oliver
Chang, Andres
Akhtar, Akil
Gamarra, Estefany L. Bocangel
Matia, Hayley
McCook-Veal, Ashley A.
Switchenko, Jeffrey
Nasti, Tahseen H.
Green, Felicia
Saini, Manpreet
Wieland, Andreas
Pinsky, Benjamin A.
Solis, Daniel
Dhodapkar, Madhav V.
Carlisle, Jennifer
Ramalingam, Suresh
Ahmed, Rafi
Suthar, Mehul S.
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title_full BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title_fullStr BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title_full_unstemmed BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title_short BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
title_sort ba.5 bivalent booster vaccination enhances neutralization of xbb.1.5, xbb.1.16 and xbb.1.9 variants in patients with lung cancer
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663480/
https://www.ncbi.nlm.nih.gov/pubmed/37990024
http://dx.doi.org/10.1038/s41541-023-00779-8
work_keys_str_mv AT valanparambilrajeshm ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT laililin ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT johnsmargareta ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT davisgardnermeredith ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT lindermansusannel ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT mcphersontarrantoliver ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT changandres ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT akhtarakil ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT gamarraestefanylbocangel ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT matiahayley ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT mccookvealashleya ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT switchenkojeffrey ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT nastitahseenh ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT greenfelicia ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT sainimanpreet ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT wielandandreas ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT pinskybenjamina ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT solisdaniel ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT dhodapkarmadhavv ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT carlislejennifer ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT ramalingamsuresh ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT ahmedrafi ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer
AT sutharmehuls ba5bivalentboostervaccinationenhancesneutralizationofxbb15xbb116andxbb19variantsinpatientswithlungcancer

Ejemplares similares